Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed) | RFA GM 19 001

Frequently Asked Questions (FAQs)

What is this funding opportunity?

This is an NIH Small Business Innovation Research (SBIR) funding opportunity (RFA-GM-19-001) focused on addressing reproducibility problems in human induced pluripotent stem cell (iPSC) research and use.

What problem is the FOA trying to solve?

The FOA targets a persistent bottleneck in the iPSC field: inconsistent, hard-to-reproduce outcomes. The announcement highlights major variability in (1) reprogramming efficiency, (2) genomic stability over time in culture, and (3) reliable differentiation into specific target tissues.

Why is iPSC reproducibility such a concern, according to the announcement?

Because variability reduces confidence in experimental findings, makes cross-lab comparisons harder, and creates obstacles for translational work and future clinical applications. The FOA notes that even iPSC lines derived from the same original donor sample can behave differently.

What kinds of differences can occur even when iPSC lines come from the same donor sample?

The FOA states that lines made from the same original donor material (for example, a single fibroblast or tissue specimen) may still show differences in growth rate, stability in culture, and downstream developmental potential (how well they can differentiate into desired cell types).

Who is this grant intended to support?

The FOA is aimed at small businesses developing new methods, tools, or workflows that make iPSC work more standardized, reliable, and cost-effective across the full iPSC lifecycle.

What is the overall scope of projects the FOA is looking for?

The scope is broad and includes improvements at essentially every stage of iPSC use: starting material selection and handling; reprogramming into pluripotency; routine growth and expansion; long-term maintenance and stability; storage and recovery of lines; and differentiation into desired cell types.

Does the FOA address issues that happen when iPSC processes are scaled up?

Yes. The announcement emphasizes challenges that arise when scaling iPSC cultures to the quantities needed for research or downstream applications, especially maintaining consistency over time and preventing phenotype drift or other changes that reduce usefulness.

What kinds of solutions does NIH want small businesses to develop?

Solutions can include new methods, tools, or workflows designed to improve standardization, reliability, and cost-effectiveness. The FOA frames the goal as producing practical, deployable approaches that reduce variability and improve comparability across experiments, sites, and investigators.

Which parts of the iPSC lifecycle are explicitly in scope?

The FOA explicitly includes: (1) starting material selection and handling, (2) reprogramming, (3) routine growth and expansion, (4) long-term maintenance and stability, (5) storage and recovery/banking, and (6) differentiation into desired cell types.

What sources of iPSC variability are called out in the announcement?

The FOA describes multiple drivers of inconsistency, including variability from donor material, reprogramming approaches, cell culture conditions, storage/banking practices, and problems related to line identification and authentication.

How can donor material contribute to variability?

The FOA states that variability may begin with the donor material itself, including donor age, the tissue type collected, the anatomical source (where in the body the tissue came from), and the donor's physiological condition or disease state.

How can the reprogramming approach contribute to differences?

The announcement notes that the reprogramming method can introduce differences, whether it relies on transcription factors, small molecules, or techniques such as cell fusion.

What routine culture decisions are noted as potential sources of inconsistency?

The FOA highlights that media formulation, growth factors, substrate, oxygen conditions, passaging methods, and other culture parameters can influence whether iPSCs remain stable and truly pluripotent.

Does the FOA mention genomic stability and drift over time?

Yes. Genomic stability over time is identified as a key reproducibility concern, and the FOA also emphasizes the challenge of keeping cells consistent over time without drifting in phenotype or acquiring changes that reduce usefulness.

Why do storage and recovery practices matter for reproducibility?

The FOA flags that freezing and thawing can introduce selection pressures or changes that may affect later performance, making storage practices and cell line banking methods an important part of the reproducibility problem.

Is iPSC line identification and authentication part of the problem the FOA wants to address?

Yes. The FOA identifies a research infrastructure issue: multiple investigators need to reliably identify and authenticate iPSC lines so that mix-ups or misidentification do not undermine results.

What funding mechanism is being used?

The opportunity is offered under the NIH SBIR program using the R44 activity code (commonly associated with SBIR Phase II).

Are clinical trials allowed under this opportunity?

No. The FOA is labeled "Clinical Trial Not Allowed," meaning supported projects should not include clinical trial activities.

Who is eligible to apply?

Eligible applicants are small businesses. The information provided also states that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible.

Are any foreign activities allowed at all?

The notice indicates that foreign components may be allowed under NIH policy definitions. In practice, this typically means limited project elements could be performed abroad if justified and compliant with NIH rules, even though foreign institutions and non-U.S. components of U.S. organizations are not eligible to apply as applicants.

What is the award ceiling mentioned in the information provided?

The award ceiling listed is $375,000.

What are the key dates provided?

The NIH posting/creation date provided is May 21, 2019, and the original closing date provided is January 6, 2020.

Are CFDA numbers associated with this opportunity?

Yes. The opportunity is listed under multiple CFDA numbers, reflecting NIH program and institute involvement across several catalogs.

What is the intended outcome or impact of projects funded under this FOA?

The FOA aims to push the iPSC field toward practical, deployable solutions that reduce iPSC variability, improve line stability and differentiation reliability, and make results more comparable across experiments, sites, and investigators.